GSK, the manufacturer of the antibody-drug conjugate belantamab mafodotin-blmf (Blenrep), has announced positive top-line findings from the phase 3 DREAMM-8 trial for belantamab mafodotin combined with pomalidomide and dexamethasone in...

The FDA’s Oncologic Drugs Advisory Committee unanimously voted that ciltacabtagene autoleucel (cilta-cel; Carvykti) offers more benefits than risks for treating adult patients with relapsed/refractory multiple myeloma who have had at...

Plasma cell dyscrasias (PCDs), like multiple myeloma, are hematologic disorders that lead to compromised immune responses, making vaccinations, particularly against influenza, less effective in patients with PCDs due to their...

A study assessed treatments for myeloma, noting advancements in patient outcomes due to proteasome inhibitors and immunomodulatory drugs, yet acknowledging persistently poor results in high-risk cases marked by rapid disease...

Researchers evaluated the efficacy and safety of denosumab compared to zoledronic acid in treating advanced cancer with bone metastasis. Extensive literature searches in MEDLINE, EMBASE, and the Cochrane library databases...

Researchers drew an analogy between the evolution of chimeric antigen receptor T-cell (CAR-T) therapy for plaque psoriasis (PsO) and the historical development of the Ford Model T, highlighting the transformative...